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Risk Factors for Chronic Graft Dysfunction in 918 Renal Transplants
A. Mota, A. Figueiredo, F. Maca´rio, F.X. Cunha, L. Freitas, B. Parada, C. Bastos, and L. Furtado
CHRONIC rejection or chronic allograft dysfunction(CD) persists as one of the most prevalent causes of
long-term kidney graft loss.1,2 As a consequence, the long-
term survival and half-life of grafts remains poor, despite
optimistic results from a recent publication.1 Chronic allo-
graft dysfunction is a process of gradual destruction of the
kidney graft, dominated by progressive vascular obliteration
and other structural changes resulting in fibrosis.3 The
evolution to CD is caused by two types of factors: nonim-
munologic and immunologic.3,4 The aim of this study was to
investigate the incidence, causes, and effects of CD among
a series of 918 renal transplants.
PATIENTS AND METHODS
We analyzed 1000 consecutive renal transplants performed in our
Institution between July 1980 and February 2001:985 were from
cadaver and 15 from living related donors. To define CD we only
considered grafts with a minimum survival of 6 months, excluding
those transplants lost before 6 months regardless of the specific
reason—technical, acute rejection (AR), or death.5 We defined CD
as a progressive decline in renal function with a serum creatinine
(SCr) 2.5 mg/dL. (Patients with a stable suboptimal renal func-
tion were not considered.) When the 82 grafts lost before reaching
6 months were excluded, 918 transplants had at least a year of
follow-up.
We investigated the following parameters from the donor (age,
cause of death, perfusion solution, cold ischemia time [CIT], and
SCr before retrieval), from the recipient (age, weight, associated
pathology, HLA mismatches, and immunosuppression), and from
the transplant course (delayed graft function [DGF] and AR). We
also studied AR and graft loss due to CD, and the influence of
cyclosporine (CyA) dosage and SCr at 1 year on CD. We did not
consider sensitization because the panel reactive antibody (PRA)
level was irrelevant (2%). The cytomegalovirus status was not
available.
A database was constructed from the records of all donors and
recipients. A multivariate analysis was performed using logistic
regression and univariate techniques and the Fishers Exact Test.
We used the Kaplan Meier method to calculate survival and the
log-rank test to compare survival rates between the two groups
(with CD or without CD). For all tests, a P value  .05 was
considered significant (two-tailed).
RESULTS
The CD was diagnosed in 239 (26%) of the 918 renal
transplants. Multivariate analysis showed that the risk fac-
tors for CD were donor age 45 years (46% vs 22%),
cerebrovascular stroke as cause of death in cadaver donors
(40% vs 25%), graft perfusion with Euro-Collins solution
(37% vs 19%), DGF (40% vs 25%), and AR (44% vs 16%)
(Table 1). The immunosuppressive regimen of azathioprine
(Aza)  prednisone (Pred) was associated with the highest
(37%) incidence of CD and mycophenolate mofetil (MMF)
 CyA  Pred with the lowest (13%) risk. In this series of
renal transplants, CD emerged as the second cause of graft
failure, with a rate of 30.6%, after death with a functioning
graft (DWFG) with a 40.6% rate. We found a clear
influence of AR on CD as a cause of graft loss: with 0, 1, or
1 AR episodes the graft loss due to CD was 22%, 43.5%,
and 59%, respectively. The 1-year SCr significantly corre-
lated with later development of CD (40% of CD with SCr
1.2 mg/dL vs 12% of CD with SCr 1.2 mg/dL). Graft
survival rates at 1, 3, 5, 10, and 15 years were 98%, 86%,
68%, 36%, and 23% in the CD group, respectively, and
99%, 95%, 92%, 84%, and 74% in the group without CD,
respectively. These differences in graft survival were statis-
tically significant (P .000) (Fig 1). Patient survival rates at
1, 3, 5, 10, and 15 years were 99%, 96%, 90%, 70%, and
57% in the CD group, respectively, and 99%, 96%, 92%,
85%, and 75% in the group without CD, respectively. These
differences in graft survival were also statistically significant
(P  .0016).
DISCUSSION
The exceptional graft and patient survival results, mainly in
the first year, are a consequence of having excluded from
the study all grafts that were lost before reaching 6 months’
survival.
Like many other investigators, our results (Table 1) have
shown the influence of donor age (45 years) and AR in
the development of CD.2,3 Kidneys from pediatric donors
(15 years) and from older donors (55 years) were
associated with poorer results,6 probably related to their
reduced nephron mass, favoring a hyperfiltration process
(mainly when creatinine clearance is less than 60 mL/min)
with functional overload and subsequent tissue damage of
the remaining renal mass.3,4,6 Acute rejection, with its
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immunological injury, is the factor most relevant to the high
incidence of CD.2,3,7 The AR episodes are associated with
local cytokine release, inducing progressive nephron dam-
age and renal mass destruction, with development of a
fibrotic repair that ends in CD.3 Hyperfiltration of the
remnant nephrons, leading to glomerulosclerosis, also plays
a role in the evolution to organ failure.3,7
Our analysis also demonstrated a powerful influence of
AR in the development of CD (Table 1): in the absence of
AR the CD rate was 16%, but with one or more AR
episodes CD appeared in 44% of cases. We correlated AR
with CD and with graft loss, concluding that both CD and
graft losses were strongly influenced by previous AR:
without AR, 22% of the graft losses were due to CD and
with one AR episode, 43.5% of the graft losses were caused
CD.
Another factor that appeared to have influence on the
development of CD was the perfusion solution. (Table 1).
Grafts perfused with University of Wisconsin (UW) solu-
tion showed better outcomes. Immunosuppression also had
a significant influence on the occurrence of CD. The
immunosuppressive regimen with MMF was associated
with a lower rate of CD. We must be cautious as the
follow-up of our patients treated with MMF is relatively
short (4 years), but the significant decrease in AR incidence
with MMF allows us to hope, in the future, for a corre-
sponding reduction in CD.8 One of the most interesting
findings in our study was the significant predisposition for
patients with SCr 1.2 mg/dL at 1 year to develop CD,
particularly considering that we excluded grafts that were
lost in the first 6 months. In these patients we observed a
higher risk (Table 1) for CD, probably because many
patients had began the evolution to CD in the first year
after transplantation, as is suggested by others.5
To prevent CD it is essential to decrease graft injury by
both immune and nonimmune mechanisms,7 a goal that
may be achieved by reducing the number and severity of
AR episodes with more effective and less toxic immunosup-
pression and by optimizing the age and weight matching
between donor and recipient.9 This strategy and the new
immunosuppressive agents may explain why Takemoto et
al5 observed a tendency to a reduction in the incidence of
CD from 1995 to 1998, accompanying a decreased AR rate.
In this study we conclude that older donor age, perfusion
with Euro-Collins solution, immunosuppression with aza-
thioprine and prednisone and mainly acute rejection epi-
sodes were most significant risk factors for CD. In our series
CD emerged as the second cause of graft loss, namely
30.5%. The CD contributed significantly to poorer graft
survival and patient survival. An SCr level above 1.2 mg/dL
at the end of the first year prematurely anticipates the later
development of CD.
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Table 1. Risk Factors for Chronic Allograft Dysfunction
Factors P Value Odds Ratio CI 95%
Donor age 45 years .000 3.563 2.303–5.508
Donor cause of death (CVS) .033 1.706 1.044–2.788






Azathioprine  prednisone .000 2.675 1.422–5.636
DGF .027 1.573 1.068–2.317
Acute rejection .000 4.074 2.976–5.579
CYA dose 5 mg/kg/d at 1 year NS
SCr at 1 year 1.2 mg/dL .000 4.871 3.475–6.864
Abbreviations: CVS, cerebrovascular stroke; CIT, cold ischemia time; DGF,
delayed graft function; CYA, cyclosporine; SCr, serum creatinine.
Fig 1. Comparison of graft actuarial survival without CD and
with CD (Kaplan-Meier Method.
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